Type 2 diabetes durg name
Reading File
Searching the Web
Type 2 diabetes drug names classes 2025
Here is a complete overview of all drug classes and names used in Type 2 Diabetes:
Type 2 Diabetes - Drug Classes & Names
1. Biguanides (First-Line)
| Generic Name | Brand Name |
|---|---|
| Metformin | Glucophage, Fortamet, Glumetza |
- Mechanism: Reduces hepatic glucose output, improves insulin sensitivity
- First-line for all T2DM patients unless contraindicated
- Weight neutral, low cost, no hypoglycemia risk
2. GLP-1 Receptor Agonists (Injectable & Oral)
| Generic Name | Brand Name |
|---|---|
| Semaglutide | Ozempic (inject), Wegovy, Rybelsus (oral) |
| Liraglutide | Victoza |
| Dulaglutide | Trulicity |
| Exenatide | Byetta, Bydureon |
| Tirzepatide | Mounjaro (also GIP agonist) |
- Mechanism: Stimulate insulin release, suppress glucagon, slow gastric emptying
- Significant weight loss, cardiovascular benefit
3. SGLT2 Inhibitors
| Generic Name | Brand Name |
|---|---|
| Empagliflozin | Jardiance |
| Dapagliflozin | Farxiga |
| Canagliflozin | Invokana |
| Ertugliflozin | Steglatro |
- Mechanism: Block glucose reabsorption in kidneys - glucose excreted in urine
- Heart failure and chronic kidney disease (CKD) protection
4. DPP-4 Inhibitors ("Gliptins")
| Generic Name | Brand Name |
|---|---|
| Sitagliptin | Januvia |
| Linagliptin | Tradjenta |
| Saxagliptin | Onglyza |
| Alogliptin | Nesina |
| Vildagliptin | Galvus |
- Mechanism: Inhibit DPP-4 enzyme, increase incretin levels
- Weight neutral, no hypoglycemia, generally well tolerated
5. Sulfonylureas
| Generic Name | Brand Name |
|---|---|
| Glimepiride | Amaryl |
| Glipizide | Glucotrol |
| Glyburide (Glibenclamide) | DiaBeta, Micronase |
| Glibenclamide | Daonil |
- Mechanism: Stimulate insulin secretion from beta cells
- Inexpensive but risk of hypoglycemia and weight gain
6. Thiazolidinediones (TZDs / "Glitazones")
| Generic Name | Brand Name |
|---|---|
| Pioglitazone | Actos |
| Rosiglitazone | Avandia |
- Mechanism: Activate PPAR-gamma, improve insulin sensitivity
- Avoid in heart failure; causes weight gain and fluid retention
7. Meglitinides
| Generic Name | Brand Name |
|---|---|
| Repaglinide | Prandin |
| Nateglinide | Starlix |
- Mechanism: Short-acting insulin secretagogues - taken before meals
- Useful for postprandial glucose control
8. Alpha-Glucosidase Inhibitors
| Generic Name | Brand Name |
|---|---|
| Acarbose | Precose, Glucobay |
| Miglitol | Glyset |
- Mechanism: Delay carbohydrate absorption in the gut
- GI side effects (bloating, gas) are common
9. Dual GIP/GLP-1 Agonist (Newer)
| Generic Name | Brand Name |
|---|---|
| Tirzepatide | Mounjaro, Zepbound |
- Mechanism: Activates both GIP and GLP-1 receptors
- Superior glucose and weight reduction compared to standalone GLP-1 agonists
10. Insulin (used in advanced T2DM)
| Type | Examples |
|---|---|
| Rapid-acting | Aspart (NovoLog), Lispro (Humalog), Glulisine (Apidra) |
| Long-acting | Glargine (Lantus), Detemir (Levemir), Degludec (Tresiba) |
| Intermediate | NPH insulin |
11. Others (Less Commonly Used)
| Class | Drug |
|---|---|
| Bile acid sequestrant | Colesevelam (Welchol) |
| Dopamine-2 agonist | Bromocriptine-QR (Cycloset) |
| Amylin analogue | Pramlintide (SymlinPen) |
Quick Reference: Treatment Priority
1st Line: Metformin
2nd Line: GLP-1 agonist or SGLT2 inhibitor (if CV/renal disease)
3rd Line: DPP-4 inhibitor, Sulfonylurea, or TZD
Advanced: Insulin therapy
Note: The 2025 ADA/EASD guidelines favor GLP-1 receptor agonists and SGLT2 inhibitors early in treatment due to proven cardiovascular and kidney-protective benefits, independent of HbA1c levels.
Type 1
Here are all the drugs used in Type 1 Diabetes:
Type 1 Diabetes - Drug Names
In T1DM, the pancreas produces little to no insulin, so insulin replacement is the cornerstone of treatment. Unlike T2DM, oral agents alone are not sufficient.
1. Rapid-Acting Insulin (Mealtime / Bolus)
| Generic Name | Brand Name | Onset | Duration |
|---|---|---|---|
| Insulin Aspart | NovoLog, Fiasp | 10–20 min | 3–5 hrs |
| Insulin Lispro | Humalog, Admelog | 15–30 min | 3–5 hrs |
| Insulin Glulisine | Apidra | 10–20 min | 3–5 hrs |
| Inhaled Insulin | Afrezza | ~12 min | 1.5–3 hrs |
- Taken just before or with meals
- Covers postprandial glucose spikes
2. Short-Acting Insulin (Regular Insulin)
| Generic Name | Brand Name | Onset | Duration |
|---|---|---|---|
| Regular Human Insulin | Humulin R, Novolin R | 30–60 min | 5–8 hrs |
- Older formulation; used in insulin pumps and IV drips (ICU)
- Taken 30 minutes before meals
3. Intermediate-Acting Insulin
| Generic Name | Brand Name | Onset | Duration |
|---|---|---|---|
| NPH Insulin (Isophane) | Humulin N, Novolin N | 1–2 hrs | 12–18 hrs |
- Often combined with regular insulin (premixed formulations)
4. Long-Acting Insulin (Basal)
| Generic Name | Brand Name | Duration |
|---|---|---|
| Insulin Glargine U-100 | Lantus, Basaglar | ~24 hrs |
| Insulin Glargine U-300 | Toujeo | >24 hrs |
| Insulin Detemir | Levemir | 18–22 hrs |
| Insulin Degludec | Tresiba | >42 hrs |
- Given once or twice daily to cover basal glucose needs
- No pronounced peak - smoother, more stable action
5. Ultra-Long-Acting Insulin
| Generic Name | Brand Name | Duration |
|---|---|---|
| Insulin Degludec | Tresiba | 42+ hrs |
| Icodec (once-weekly) | Awiqli (newest, 2024) | ~7 days |
- Icodec is a once-weekly basal insulin - newest addition for T1DM management
6. Premixed Insulins
| Generic Name | Brand Name |
|---|---|
| 70% NPH / 30% Regular | Humulin 70/30, Novolin 70/30 |
| 75% Lispro Protamine / 25% Lispro | Humalog Mix 75/25 |
| 70% Aspart Protamine / 30% Aspart | NovoLog Mix 70/30 |
- Convenient but less flexible - not preferred for tight T1DM control
7. Adjunct Non-Insulin Drugs (Add-on to Insulin)
These do not replace insulin but help improve control:
| Drug | Class | Benefit |
|---|---|---|
| Pramlintide (SymlinPen) | Amylin analogue | Reduces postprandial glucose, weight loss |
| Metformin | Biguanide | Used off-label in overweight T1DM patients |
| Dapagliflozin (Farxiga) | SGLT2 inhibitor | FDA-approved adjunct in T1DM (risk of DKA - monitor carefully) |
| Sotagliflozin (Inpefa) | SGLT1/2 inhibitor | Approved as adjunct; reduces HbA1c and weight |
⚠️ SGLT inhibitors in T1DM carry a risk of euglycemic DKA - use with caution
8. Delivery Devices
| Device | Examples |
|---|---|
| Insulin Pen | FlexPen, KwikPen, SoloStar |
| Insulin Pump (CSII) | Medtronic MiniMed, Tandem t:slim X2 |
| Closed-loop (Artificial Pancreas) | Omnipod 5, Tandem Control-IQ |
| Inhaler | Afrezza MannKind device |
Basal-Bolus Regimen (Standard T1DM Regimen)
Morning: Long-acting insulin (Glargine/Detemir/Degludec) — Basal
+ Before each meal: Rapid-acting insulin (Aspart/Lispro/Glulisine) — Bolus
Total daily dose: ~0.5–1.0 units/kg/day
→ 50% basal + 50% bolus
Summary Table
| Category | Key Drugs |
|---|---|
| Rapid-acting | Aspart, Lispro, Glulisine, Afrezza |
| Short-acting | Regular (Humulin R) |
| Intermediate | NPH (Humulin N) |
| Long-acting (Basal) | Glargine, Detemir, Degludec |
| Once-weekly basal | Icodec (Awiqli) |
| Adjuncts | Pramlintide, Dapagliflozin, Sotagliflozin |
The gold standard for T1DM is the basal-bolus insulin regimen, ideally combined with continuous glucose monitoring (CGM) for optimal control.
Type1 and 2 diabetes difference
Not drugs explain it
Here is a clear, detailed comparison of Type 1 vs Type 2 Diabetes - no drugs, just the disease itself:
Type 1 vs Type 2 Diabetes - Complete Comparison
1. Basic Definition
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| What it is | Autoimmune destruction of insulin-producing cells | Insulin resistance + progressive insulin deficiency |
| Core problem | Body makes NO insulin | Body makes insulin but can't use it effectively |
| Old names | Juvenile diabetes, Insulin-dependent DM | Adult-onset diabetes, Non-insulin-dependent DM |
2. Cause & Mechanism
Type 1
- The immune system attacks and destroys beta cells in the pancreas (islets of Langerhans)
- Result: absolute insulin deficiency - zero or near-zero insulin production
- Trigger: genetic susceptibility + environmental factors (viral infection, etc.)
- Not caused by diet or lifestyle
Type 2
- Cells in the body become resistant to insulin (especially muscle, liver, fat cells)
- Pancreas initially compensates by making more insulin
- Over time, beta cells burn out and insulin production also drops
- Strongly linked to obesity, inactivity, and diet
3. Who Gets It
| Feature | Type 1 | Type 2 |
|---|---|---|
| Age of onset | Usually childhood / young adults (any age possible) | Usually adults 40+ (increasingly in younger people) |
| Body weight | Typically lean or normal weight | Commonly overweight or obese |
| Family history | Some genetic risk (~10% if parent has it) | Strong genetic link (~40% if one parent has it) |
| Ethnicity | More common in Caucasians | More common in South Asians, African, Hispanic populations |
| % of all diabetes | ~5-10% | ~90-95% |
4. Onset of Symptoms
| Feature | Type 1 | Type 2 |
|---|---|---|
| Speed of onset | Sudden / acute (days to weeks) | Gradual / silent (years) |
| Severity at diagnosis | Often dramatic - can present with DKA | Often mild or asymptomatic at diagnosis |
| How discovered | Usually from symptoms | Often found on routine blood test |
5. Classic Symptoms (The "3 Polys")
Both types share the same classic symptoms, but T1 presents much more dramatically:
| Symptom | Type 1 | Type 2 |
|---|---|---|
| Polyuria (excess urination) | Marked | Mild to moderate |
| Polydipsia (excess thirst) | Marked | Mild |
| Polyphagia (excess hunger) | Marked | Variable |
| Weight loss | Significant, rapid | Rare (usually weight gain) |
| Fatigue | Severe | Mild |
| Blurred vision | Yes | Yes |
| DKA at diagnosis | Common (~30%) | Rare |
6. Pathology (What's Happening Inside)
| Feature | Type 1 | Type 2 |
|---|---|---|
| Insulin level | Very low / absent | Normal or high early → low later |
| C-peptide | Low / undetectable | Normal or elevated early |
| Autoantibodies | Present (anti-GAD, anti-IA2, anti-ZnT8, ICA) | Absent |
| Pancreatic beta cells | Destroyed | Dysfunctional / exhausted |
| Insulin resistance | Not primary feature | Core feature |
| Glucagon | Dysregulated | Elevated (contributes to hyperglycemia) |
7. Investigations / Lab Tests
| Test | Type 1 | Type 2 |
|---|---|---|
| Fasting blood glucose | High | High |
| HbA1c | High | High |
| C-peptide | Low/absent | Normal or high |
| Autoantibodies (GAD65, IA-2) | Positive | Negative |
| Ketones | Often positive | Usually negative |
| Insulin level | Very low | Normal/high early |
8. Complications (Same for Both)
Short-term (Acute)
| Complication | Type 1 | Type 2 |
|---|---|---|
| DKA (Diabetic Ketoacidosis) | Very common | Rare |
| HHS (Hyperosmolar Hyperglycemic State) | Rare | More common |
| Hypoglycemia | Common | Less common |
Long-term (Chronic) - Same in Both
- Microvascular: Retinopathy (eyes), Nephropathy (kidneys), Neuropathy (nerves)
- Macrovascular: Heart attack, Stroke, Peripheral artery disease
- Others: Diabetic foot, ED, Gastroparesis
9. Prevention
| Type 1 | Type 2 | |
|---|---|---|
| Preventable? | NO - autoimmune, cannot be prevented | YES - lifestyle changes can prevent or delay it |
| Reversible? | NO | Partially yes - remission possible with weight loss |
| Screening | Not routine (unless family history) | Routine screening recommended from age 35 |
10. Visual Summary
TYPE 1 TYPE 2
──────────────────────────────────────────────────
Autoimmune Lifestyle/Genetic
No insulin made Insulin not used well
Thin patient Obese patient
Sudden onset Silent/gradual onset
Young age Older age
DKA risk HHS risk
Autoantibodies (+) Autoantibodies (-)
C-peptide low C-peptide normal/high
NOT preventable PREVENTABLE
Needs insulin always May manage without insulin
Key Takeaway: T1DM is an autoimmune disease where the body destroys its own insulin factory. T2DM is a metabolic disease where the body's cells stop listening to insulin, largely driven by lifestyle factors - though genetics play a role in both.
This is a shared conversation. Sign in to Orris to start your own chat.